136-OR: Examining New-Onset Type 1 Diabetes Educational Practices among Centers in the T1D Exchange Quality Improvement Collaborative (T1DX-QI)

Background: The diagnosis of Type 1 Diabetes (T1D) requires immediate comprehensive education for people with T1D (PWD) and their caregivers. Educational content, delivery, methodology, location, and duration are not standardized. This study aims to evaluate the current state of new-onset diabetes education among T1DX-QI centers. Methods: A survey was administered from July to September 2023 to 55 T1DX-QI centers. Descriptive analysis was completed. Results: 50 of 55 centers (91%) completed the survey. Education consists of 5+ sessions (15%), 4 sessions (42%), 3 sessions (17%), 2 sessions (17%), and 1 session (2%). Communication immediately after diagnosis between PWD/family Provention Bio, Inc. E.L. Ospelt: None. O. Ebekozien: Advisory Panel; Sanofi, Medtronic. Research Support; Vertex Pharmaceuticals Incorporated. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; Medtronic, Lilly Diabetes, Abbott, Dexcom, Inc. C. Schulmeister: None. N. Rioles: None. H. Hardison: None. D. Plante: None. A. Mucci: None. N.N. Mathioudakis: None. V. Raman: None. M.A. Clements: Research Support; Abbott. Consultant; Glooko, Inc. Research Support; Dexcom, Inc. Funding Helmsley Charitable Trust